Companies Dominating the S1P Receptor Modulator Drugs Landscape
- Novartis International AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Bristol Myers Squibb Company
- Johnson & Johnson
- Biogen Inc.
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd.
- Quality Pharma Products Pvt. Ltd.
- Pfizer Inc.
- Sanofi S.A.
- Medicinum Healthcare Pvt. Ltd.
Browse Key Market Insights with Data Illustration:
In the News
- Bristol Myers Squibb announced a definitive agreement to acquire Mirati Therapeutics, a commercial-stage targeted oncology company specializing in KRAS G12C inhibitors. This USD 4.8 billion acquisition adds the FDA-approved KRAZATI® (adagrasib) to BMS's portfolio, along with promising early-stage assets targeting KRAS and other driver mutations.
- BMS and Seagen announced a collaboration to launch a Phase 3 trial evaluating ADCETRIS® in combination with chemotherapy for treatment-naive adult patients with Hodgkin lymphoma. This partnership leverages the strengths of both companies to pursue potentially curative options for this cancer.
